ONCO — Oncopeptides AB Income Statement
0.000.00%
Last trade - 00:00- SEK409.43m
- SEK352.79m
- SEK31.65m
Annual income statement for Oncopeptides AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 118 | 8.36 | 35.2 | 31.6 |
| Cost of Revenue | |||||
| Gross Profit | — | 65.2 | 8.35 | 36.3 | 29 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,591 | 1,539 | 358 | 289 | 315 |
| Operating Profit | -1,591 | -1,421 | -349 | -253 | -283 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1,592 | -1,421 | -338 | -248 | -284 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1,595 | -1,430 | -338 | -249 | -285 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1,595 | -1,430 | -338 | -249 | -285 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1,595 | -1,430 | -338 | -249 | -285 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -18.2 | -13.5 | -2.93 | -1.96 | -1.71 |
| Dividends per Share |